Search results
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June...
Benzinga· 6 days agoMid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX,...
Cramer's Lightning Round: 'Let's stay away' from Unity Software
CNBC· 9 hours ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks· 3 hours agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 2 hours agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
12 Health Care Stocks Moving In Monday's Intraday Session - Curis (NASDAQ:CRIS), CNS Pharma...
Benzinga· 5 days agoCuris CRIS stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. Skye Bioscience SKYE stock fell 15.0% to $9.3 ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 3 days agoModerna stock went public at 23 in late 2018. In 2020, shares rocketed more than 434%. The...from a...
Abbott Labs Enters The U.S. Obesity Arena
Investor's Business Daily· 5 days agoThe Food and Drug Administration signed off on Lingo and Libre Rio — vastly expanding Abbott's market in the U.S. Both are continuous glucose monitors,...
Eli Lilly Pushes Alzheimer's Stocks Lower On FDA Win
Investor's Business Daily· 4 days agoDespite the stock move, analysts largely expect donanemab to gain FDA approval. Late Monday, the advisors to the FDA voted unanimously that the clinical...
Moderna Falls, Though Says Covid/Flu Shot Topped Rivals
Investor's Business Daily· 5 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoIt will be important to watch how Pfizer stock performs as the company shores up its pipeline and...
